T
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Price:
5 870 ILS
0.95%
Market Closed
Updated:
May 12, 2024
Teva Pharmaceutical Industries Ltd
Cost of Revenue
|
Teva Pharmaceutical Industries Ltd
Cost of Revenue Peer Comparison
Comparables:
TARO
I
INCR
MDWD
R
REKA
C
CSURE
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Cost of Revenue
-$7.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Cost of Revenue
-$317.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-6%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Cost of Revenue
-₪265.3m
|
CAGR 3-Years
-146%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-63%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Cost of Revenue
-$15.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Cost of Revenue
-₪235.6m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-3%
|
|
C
|
Cannassure Therapeutics Ltd
TASE:CSURE
|
Cost of Revenue
-₪30.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Teva Pharmaceutical Industries Ltd's Cost of Revenue?
Cost of Revenue
-7.9B
USD
-7.9B
USD
Based on the financial report for Dec 31, 2023, Teva Pharmaceutical Industries Ltd's Cost of Revenue amounts to -7.9B USD.
What is Teva Pharmaceutical Industries Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
2%
2%
Over the last year, the Cost of Revenue growth was -5%. The average annual Cost of Revenue growth rates for Teva Pharmaceutical Industries Ltd have been 4% over the past three years , 6% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
